Loading...
Biora Therapeutics, Inc.
BIOR•NASDAQ
Healthcare
Biotechnology
$0.22
$0.00(0.00%)

Over the past four quarters, Biora Therapeutics, Inc. demonstrated steady revenue growth, increasing from $872000.00 in Q4 2023 to $32000.00 in Q3 2024. Operating income reached -$16.23M in Q3 2024, maintaining a consistent -50709% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$16.23M, reflecting operational efficiency. Net income dropped to -$18.40M, with EPS at -$5.04. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan